scholarly journals Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor prognosis

Oncotarget ◽  
2015 ◽  
Vol 6 (26) ◽  
pp. 23026-23035 ◽  
Author(s):  
Guohong Zhang ◽  
Yabin Cheng ◽  
Guangdi Chen ◽  
Yun Tang ◽  
Gholamreza Ardekani ◽  
...  
Keyword(s):  
Tumor Suppressors ◽  
Poor Prognosis ◽  
Primary Melanoma ◽  
Melanoma Patients ◽  
Patients With Poor Prognosis

scholarly journals Postoperative assessment of malignant melanoma aggressiveness for further treatment personalization

2021 ◽  
Vol 11 (2) ◽  
pp. 45-51
Author(s):  
S. A. Yargunin ◽  
Ya. N. Shoikhet ◽  
A. F. Lazarev
Keyword(s):  
Poor Prognosis ◽  
Primary Melanoma ◽  
Surgical Removal ◽  
Tumor Aggressiveness ◽  
Postoperative Assessment ◽  
Risk Of Progression ◽  
Grade Ii ◽  
Individualize Treatment ◽  
Patients With Poor Prognosis ◽  
Treatment Personalization

The aim of the study was to develop, implement and evaluate a method for predicting the aggressiveness of primary melanoma after surgical removal.It was established that the method for predicting tumor aggressiveness allows to determine the degree of aggressiveness, life expectancy, and to identify patients with poor prognosis in order to individualize treatment. The survival rate of patients was found to depend on the degree of aggressiveness of the tumor. A group of patients with stages 0-IIa (16,4 %) and tumor aggressiveness Grade II was identified as having a potentially high risk of progression, which can help individualize treatment for this category of patients. Using the method for predicting disease progression may potentially expand the scope of indications for further personalized treatment.

Abstract A33: Loss of tumor suppressors KAI1 and p27 identifies a unique subgroup of primary melanoma patients with poor survival

2015 ◽  
Author(s):  
Yabin Cheng ◽  
Guohong Zhang ◽  
Yun Tang ◽  
Guangdi Chen ◽  
Gholamreza Safaee ◽  
...  
Keyword(s):  
Tumor Suppressors ◽  
Primary Melanoma ◽  
Poor Survival ◽  
Melanoma Patients

Correlation analysis of gene and immune microenvironment for 87 melanoma cases.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e21555-e21555
Author(s):  
Lanqun Qin ◽  
Yu Ren ◽  
Lianjun Zhao ◽  
Yirong Wu ◽  
Mengke Zhao ◽  
...  
Keyword(s):  
Copy Number ◽  
Poor Prognosis ◽  
Gene Copy Number ◽  
Primary Melanoma ◽  
Gene Copy ◽  
Immune Microenvironment ◽  
Braf Mutations ◽  
Melanoma Patients ◽  
The Difference ◽  
Copy Number Amplification

e21555 Background: To map the genome of Chinese melanoma patients and explore its correlation with the expression of tumor immune microenvironmental indicators. Methods: Next generation sequencing was performed on 87 cases of primary melanoma that had been surgically removed from Nanjing Drum Tower Hospital from July 2010 to May 2017. Immunohistochemistry was carried out to detect the expressions of PD1, PDL1, CD3+TIL, MSH2, MSH6, PMS2 and MLH1. Results: BRAF mutations were the most common (26.4%), followed by KIT mutations (12.6%) in melanoma patients. RB1 gene copy number deletion (55%) and CDK4 (25%)/CCND1 (22.5%) gene copy number amplification were also common. The prognosis of patients could be distinguished by grouping the expression of PDL1 and TIL, and the difference may be related to the expression of PD1. There were more copy number amplication of genes with poor prognosis in PDL1-TIL- patients. Conclusions: The classification of tumors into four microenvironmental subtypes based on PDL1 and TIL expression is an appropriate method to stratify patients with different clinical outcomes. At the genetic level, there are more copy number amplification of the genes with poor prognosis in patients with TIL-PDL1- type, so the prognosis is always worse than that of patients with TIL+PDL1+ type. Gene may affect the prognosis of patients by affecting the tumor immune microenvironment.

Recommendations for identifying Crohn’s disease patients with poor prognosis

2013 ◽  
Vol 9 (1) ◽  
pp. 65-76 ◽  
Author(s):  
Pal Miheller ◽  
Lajos S Kiss ◽  
Mark Juhasz ◽  
Michael Mandel ◽  
Peter L Lakatos
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Poor Prognosis ◽  
Patients With Poor Prognosis

AC-015 Effect of laser-assisted hatching in patients with poor prognosis

2008 ◽  
Vol 16 ◽  
pp. S-23
Author(s):  
ES Lee ◽  
HJ Won ◽  
SW Yoo ◽  
HA Seok ◽  
KR Cha
Keyword(s):  
Poor Prognosis ◽  
Assisted Hatching ◽  
Patients With Poor Prognosis

scholarly journals Endoprosthetic Reconstruction for a Displaced Atypical Femoral Fracture in a Cancer Patient with Poor Prognosis

2018 ◽  
Vol 2018 ◽  
pp. 1-5
Author(s):  
Hironari Tamiya ◽  
Hiroki Hagizawa ◽  
Takaaki Nakai ◽  
Yoshinori Imura ◽  
Takaaki Tanaka ◽  
...  
Keyword(s):  
Cancer Patient ◽  
Activities Of Daily Living ◽  
Cancer Patients ◽  
Femoral Fracture ◽  
Daily Living ◽  
Poor Prognosis ◽  
Femoral Fractures ◽  
Endoprosthetic Reconstruction ◽  
Atypical Femoral Fractures ◽  
Patients With Poor Prognosis

Zoledronate or denosumab treatment is beneficial for cancer patients with bone metastasis. However, each agent may trigger atypical femoral fractures. Incomplete atypical femoral fractures can be successfully treated with prophylactic intramedullary nailing. On the other hand, intramedullary nailing for displaced atypical femoral fractures occasionally causes problems with regard to bone healing, resulting in long-term treatment. In cancer patients with poor prognosis who experience atypical femoral fractures, improvement in activities of daily living should be the priority. Thus, we performed endoprosthetic reconstruction for a displaced atypical femoral fracture in a breast cancer patient with poor prognosis to enable walking in the early stage after the operation. Two weeks after the operation, she could successfully walk. The postoperative Musculoskeletal Tumor Society score was 47%, and it had improved to almost the preoperative level before injury (50%). In conclusion, endoprosthetic reconstruction for displaced atypical femoral fractures may be a first-line treatment approach to acquire early postoperative walking ability for improving activities of daily living in cancer patients with poor prognosis.

scholarly journals Prospective, Multicenter Clinical Impact Evaluation of a 31-Gene Expression Profile Test for Management of Melanoma Patients

2018 ◽  
Vol 2 (2) ◽  
pp. 111-121 ◽  
Author(s):  
Larry D Dillon ◽  
Joseph E Gadzia ◽  
Robert S Davidson ◽  
Michael McPhee ◽  
Kyle R Covington ◽  
...  
Keyword(s):  
Gene Expression ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Tumor Biology ◽  
Primary Melanoma ◽  
Risk Class ◽  
Class 1 ◽  
Post Test ◽  
Melanoma Patients ◽  
And Performance

Objective: A 31-gene expression profile (GEP) test that has been clinically validated identifies melanoma patients with low (Class 1) or high (Class 2) risk of metastasis based on primary tumor biology.  This study aimed to prospectively evaluate the test impact on clinical management of melanoma patients.Methods:  Physicians at 16 dermatology, surgical or medical oncology centers examined patients to assess clinical features of the primary melanoma.  Recommendations for clinical follow-up and surveillance were collected.  Following consent of the patient and performance of the GEP test, recommendations for management were again collected, and pre- and post-test recommendations were assessed to determine changes in management resulting from the addition of GEP testing to traditional clinicopathologic risk factors.   Results:  Post-test management plans changed for 49% (122 of 247) of cases in the study when compared to pre-test plans. Thirty-six percent (66 of 181) of Class 1 cases had a management change, compared to 85% (56 of 66) of Class 2 cases.  GEP class was a significant factor for change in care during the study (p<0.001), with Class 1 accounting for 91% (39 of 43) of cases with decreased management intensity, and Class 2 accounting for 72% (49 of 68) of cases with increases.Conclusions: The reported study show that the 31-gene GEP test improves net health outcomes in the management of cutaneous melanoma.  Physicians used test results to guide risk-appropriate changes that match the biological risk of the tumor, including directing more frequent and intense surveillance to high-risk, Class 2 patients.

scholarly journals Hypoploidy defines patients with poor prognosis in breast cancer

2007 ◽  
Author(s):  
Elisabet Chavez-Uribe ◽  
José Cameselle-Teijeiro ◽  
Juan Viñuela ◽  
Carmen Castro-Piñeiro ◽  
Francisco Gude ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Poor Prognosis ◽  
Patients With Poor Prognosis
Sign in / Sign up

Export Citation Format

Share Document